Publications

• InspeCKD - Analysis of the use of diagnostics in patients at high risk for chronic kidney disease in German general practitioner (GP) practices

  C. Wanner, E. Schaeffner, T. Frese, C. Weber, P. Stahl, F. Scherg, F. Burckhardt, U. Opfermann, F. Radowsky, F. Mader

  PMID: 38575833 Show Details link to full text
  Study

  InspeCKD

  Year

  2024

  Keywords

  • CKD

• real-world use of teriflunomide in Germany and changes in treatment patterns over time

  B.-A. Kallmann, G. Zu Eulenburg, J.S. Kullmann, M. Mäurer

  PMID: 38808094 Show Details link to full text
  Study

  TAURUS-MS II

  Year

  2024

  Keywords

  • multiple sclerosis

• Design and Rationale of MYOFLAME-19 RCT: MYOcardial protection to reduce inFLAMmatory heart disease due to COVID-19 Infection using CMR Endpoints

  V. O. Puntmann , D. Beitzke, A. Kammerlander, I. Voges, D. D. Gabbert, M. Doerr, B. Chamling, B. Bozkurt, J. C. Kaski, E. Spatz, E. Herrmann, G. Rohde, P. DeLeuw, L. Taylor, C. Windemuth-Kieselbach, C. Harz, M. Santiuste, L. Schoeckel, J. Hirayama, P. C. Taylor, C. Berry, E. Nagel

  PMID: 39481808 Show Details link to full text
  Study

  MYOFLAME-19

  Year

  2024

  Keywords

  • cardiovascular
  • COVID-19

• New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma

  Maggie Banys-Paluchowski

  PMID: 10.1055/a-1850-9512 Show Details link to full text
  Study

  Year

  2023

  Keywords

  • HER2
  • breast cancer

• Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

  Prof Jürgen C Becker, MD PhD; Prof Selma Ugurel, MD; Prof Ulrike Leiter, MD; Prof Friedegund Meier, MD; Prof Ralf Gutzmer, MD; Prof Sebastian Haferkamp, MD; Lisa Zimmer, MD; Elisabeth Livingstone, MD; Prof Thomas K Eigentler, MD; Prof Axel Hauschild, MD: Felix Kiecker, MD; Prof Jessica C Hassel, MD; Peter Mohr, MD; Michael Fluck, MD; Ioannis Thomas, MD; Marlene Garzarolli, MD; Imke Grimmelmann, MD; Konstantin Drexler, MD; Alexandra N Spillner, PhD; Sebastian Eckhardt, MS; Prof Dirk Schadendorf, MD

  PMID: Show Details link to full text
  Study

  ADMEC-O

  Year

  2023

  Keywords

  • immunotherapy
  • nivolumab
  • Merkel cell carcinoma

• Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial

  E. Livingstone; H. Gogas; L. Kandolf-Sekulovic; F. Meier; T.K. Eigentler; M. Ziemer; P.A.M. Terheyden; A.H. Gesierich; R.A. Herbst; K.C. Kähler; D.C. Ziogas; Z. Mijuskovic; M. Garzarolli; C. Garbe; A. Roesch; S. Ugurel; R. Gutzmer; J.J. Grob; F. Kiecker; J. Utikal; C. Windemuth-Kieselbach; S. Eckhardt; L. Zimmer; D. Schadendorf

  PMID: 10.1016/j.ejca.2023.112941 Show Details link to full text
  Study

  ImmunoCobiVem

  Year

  2023

  Keywords

  • melanoma

• Breast Cancer and Genetic BRCA1/2 Testing in Routine Clinical Practice: Why, When and For Whom?

  Michael P. Lux, Peter A. Fasching

  PMID: 10.1055/a-1929-2629 Show Details link to full text
  Study

  Year

  2023

  Keywords

  • breast cancer

• A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients with Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE

  C. Dejaco, T. Mueller, O. Zamani, U. Kurtz, S. Egger, J. Resch-Passini, A. Totzauer, B. Yazdani-Biuki, T. Schwingenschloegl, P. Peichl, A. Kraus, G. W. Naerr

  PMID: 35721062 Show Details link to full text
  Study

  GO ACTIVE

  Year

  2022

  Keywords

  • rheumatoid arthritis
  • psoriatic arthritis
  • axial spondyloarthritis
  • golimumab
  • QoL
  • WPAI

• Incidental Pulmonary Nodules - What Do We Know in 2022

  Gerald Schmid-Bindert, Jens Vogel-Claussen, Sylvia Gütz, Joana Fink, Hans Hoffmann, Martin E. Eichhorn, Felix J.F. Herth

  PMID: 36228594 Show Details link to full text
  Study

  Year

  2022

  Keywords

  • lung cancer

• Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial

  L. Zimmer, A. Krackhardt, E. S. Schultz, D. Goeppner, C. Assaf, D. Trebing, E. Livingstone, D. Schadendorf

  PMID: Show Details link to full text
  Study

  IMMU-Target

  Year

  2021

  Keywords

  • pembrolizumab
  • encorafenib
  • binimetinib
  • oncology
  • BRAF mutation